Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk commences work on new US production facility

Novo Nordisk commences work on new US production facility

30th March 2016

Novo Nordisk has officially broken ground on a new production facility in Clayton, North Carolina, which will support the growth of its US operations.

The $2 billion (1.39 billion pounds) development will produce active pharmaceutical ingredients for a range of the company's current and future GLP-1 and insulin products. It is expected to become fully operational in 2020.

It will be situated adjacent to an existing 42,000 sq m facility used to assemble and package the FlexPen and FlexTouch prefilled insulin devices for the US market, and will create close to 700 new jobs.

The facility will ensure production capacity for diabetes care products in the US remains sustainable for the next decade, a period in which the prevalence of diabetes is expected to continue to grow.

Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk, said: "This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."

The company achieved double-digit growth in terms of sales, profits and earnings in 2015, achieving its financial goals for the year.ADNFCR-8000103-ID-801815536-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.